Fulvestrant - A novel estrogen receptor antagonist for the treatment of advanced breast cancer

Drugs of Today

Volumn 44, Issue 9, 2008, Pages 679-692

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FULVESTRANT; GEFITINIB; LAPATINIB; PLACEBO; TAMOXIFEN; TIPIFARNIB; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BREAST CANCER; CANCER RESISTANCE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INCREASED APPETITE; INJECTION SITE REACTION; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PAIN; POSTMENOPAUSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOEMBOLISM; URINARY TRACT INFECTION; VAGINITIS; VASODILATATION; VOMITING; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS;

EID: 57649135069     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.9.1269854     Document Type: Review

References (53)

1. Anderson, W.F., Chatterjee, N., Ershler, W.B., Brawley, O.W. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002, 76(1) : 27-36.
2. Wilcken, N., Hornbuckle, J., Ghersi, D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003, 2: CD002747.
3. Bertelli, G., Pronzato, P., Amoroso, D. et al. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988, 12(3): 307-10.
4. Love, R.R., Barden, H.S., Mazess, R.B., Epstein, S., Chappell, R.J. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994, 154(22): 2585-8.
5. Morales, M., Santana, N., Soria, A. et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 1996, 40(3): 265-70.
6. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001, 1: CD000486.
7. Howell, A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001, 7 (12, Suppl.): 4369s-75s.
8. Chia, S., Bryce, C., Gelmon, K. The 2000 EBCTCG overview: A widening gap. Lancet 2005, 365(9472): 1665-6.
9. Nabholtz, J.M., Buzdar, A., Pollak, M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18(22): 3758-67.
10. Mouridsen, H., Sun, Y., Gershanovich, M., Perez-Carrion, R., Becquart, D., Chaudri-Ross, H.A., Lang, R. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: Evidence from metastatic subgroups and a test of functional ability. Oncologist 2004, 9(5): 489-96.
11. The ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1): 45-53.
12. Thürlimann, B., Kesaviah, A., Mouridsen, H. et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol (Meeting Abstracts) 2005, 23: 6s, Abst 511.
13. Brufsky, A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006, 33(7): 13-7.
14. Wakeling, A.E., Dukes, M., Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51(15): 3867-73.
15. Robertson, J.F.R. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator - Future possibilities in breast cancer. J Steroid Biochem Mol Biol 2001, 79(1-5): 209-12.
16. Wakeling, A.E. Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol 1995, 49(11): 1545-9.
17. Wakeling, A.E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000, 7(1): 17-28.
18. Nicholson, R.I., Johnston, S.R. Endocrine therapy - Current benefits and limitations. Breast Cancer Res Treat 2005, 93(Suppl. 4): S3-10.
19. Meier, C.R., Jick, H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998, 45(6): 608-12.
20. Mounts, M.J., de Vries, E.G., Willemse, P.H., Ten Hoor, K.A., Hollema, H., Van der Zee, A.G. Tamoxifen treatment and gynecologic side effects: A review. Obstet Gynecol 2001, 97(5, Pt. 2): 855-66.
21. Osborne, C.K., Coronado-Heinsohn, E.B., Hilsenbeck, S.G. et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87(10): 746-50.
22. Martin, L.-A., Pancholi, S., Chan, C.M.W., Farmer, I., Kimberley, C., Dowsett, M., Johnston, S.R.D. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005, 12(4): 1017-36.
23. Macedo, L., Sabnis, G., Goloubeva, O., Brodie, A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 2008, 68(9): 3516-22.
24. Massarweh, S., Osborne, C.K., Jiang, S. et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neo-positive breast cancer. Cancer Res 2006, 66(16): 8266-73.
25. Okubo, S., Kurebayashi, J., Otsuki, T., Yamamoto, Y., Tanaka, K., Sonoo, H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004, 90(1): 236-44.
26. Pietras, R.J., Marquez, D., Chen, H.-W., Ayala, R., Ramos, L., Slamon, D. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 2003, 82(Suppl. 1): Abst 22.
27. Addo, S., Yates, R.A., Laight, A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002, 87(12): 1354-9.
28. Robertson, J.F., Nicholson, R.I., Bundred, N.J. et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5, 5- pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001, 61(18): 6739-46.
29. Kuter, I., Hegg, R., Singer, C.F., Badwe, R., Lowe, E., on behalf of the NEWEST investigators. Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2008, 109: Abst 589.
30. Gutteridge, E., Robertson, J.F.R., Cheung, K.L., Pinder, S., Ellis, I.O., Wakeling, A.E. Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer - Final results. Breast Cancer Res Treat 2004, 86: Abst 4086.
31. Robertson, J.F.R., Gutteridge, E., Cheung, K.L., Pinder, S., Wakeling, A. Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment. J Clin Oncol 2004, 22(14, Suppl.): Abst 536.
32. Vergote, I., Robertson, J.F.R., Kleeberg, U., Burton, G., Osborne, C.K., Mauriac, L. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003, 79(2): 207-11.
33. Robertson, J.F.R., Howell, A., Gorbunova, V.A., Watanabe, T., Pienkowski, T., Lichinitser, M.R. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005, 92(2): 169-74.
34. Howell, A., DeFriend, D.J., Robertson, J.F. et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996, 74(2): 300-8.
35. Howell, A., Robertson, J.F.R., Quaresma Albano, J. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20(16): 3396-403.
36. Osborne, C.K., Pippen, J., Jones, S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002, 20(16): 3386-95.
37. Robertson, J.F., Osborne, C.K., Howell, A. et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - A prospective combined analysis of two multicenter trials. Cancer 2003, 98(2): 229-38.
38. Jones, S.E., Pippen, J., Webster, A. A retrospective analysis of the proportion of patients responding for >1, 1.5 and 2 years in two phase III studies of fulvestrant versus anastrozole. Breast Cancer Res Treat 2004, 88(Suppl. 1): Abst 6047.
39. Howell, A., Pippen, J., Elledge, R.M. et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005, 104(2): 236-9.
40. Chia, S., Gradishar, W., Mauriac, L. et al. Double-blind, randomized placebo-controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in post-menopausal women with hormone receptor-positive advanced breast cancer: Results from EFECT. J Clin Oncol 2008, 26(10): 1664-70.
41. Howell, A., Robertson, J.F.R., Abram, P. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in post-menopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004, 22(9): 1605-13.
42. Robertson, J.F., Erikstein, B., Osborne, K.C. et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 2004, 43(8): 529-38.
43. Neven, P., Paridaens, R., Pelgrims, G. et al. Fulvestrant (Faslodex™) in advanced breast cancer: Clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 2008, 109(1): 59-65.
44. Steger, G.G., Bartsch, R., Wenzel, C. et al. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: A single-centre experience. Eur J Cancer 2005, 41(17): 2655-61.
45. Steger, G.G., Gips, M., Simon, S.D. et al. Fulvestrant ('Faslodex'): Clinical experience from the compassionate use programme. Cancer Treat Rev 2005, 31 (Supp1. 2): S10-6.
46. Robertson J.F.R, Steger, G.G., Neven, P. et al. Activity of fulvestrant in HER2 advanced breast cancer: Updated analyses. Abstract 184 presented at the American Society of Clinical Oncology Breast Cancer Symposium, September 5-7, 2008, Washington D.C.
47. Bartsch, R., Mlineritsch, B., Gnant, M. et al. The Austrian Fulvestrant Registry: Results from a prospective observation of fulvestrant in post-menopausal patients. J Clin Oncol 2008, 26(15S): 1060.
48. Mauriac, L., Pippen, J.E., Quaresma Albano, J., Gertler, S.Z., Osborne, C.K. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of post-menopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003, 39(9): 1228-33.
49. Romieu, G., Bines, J., Mauriac, L. Activity of fulvestrant in patients with visceral metastases: Results from EFECT. Breast Cancer Res Treat 2008, Submitted.
50. Robertson, J.F., Williams, M.R., Todd, J., Nicholson, R.I., Morgan, D.A., Blarney, R.W. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989, 25(3): 469-75.
51. Chia, S., Gradishar, W. Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. Breast 2008, 17 (Suppl. 3): 16-21.
52. Weinberg, O.K., Marquez-Garban, D.C., Pietras, R.J. New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat 2005, 8(4): 219-33.
53. Howell, A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006, 13(3): 689-706.